Tonix Pharmaceuticals Holding (TNXP) EBIAT (2023 - 2025)
Tonix Pharmaceuticals Holding has reported EBIAT over the past 3 years, most recently at -$46.9 million for Q4 2025.
- Quarterly results put EBIAT at -$46.9 million for Q4 2025, down 106.26% from a year ago — trailing twelve months through Dec 2025 was -$122.2 million (up 10.98% YoY), and the annual figure for FY2025 was -$121.6 million, up 11.8%.
- EBIAT for Q4 2025 was -$46.9 million at Tonix Pharmaceuticals Holding, down from -$31.8 million in the prior quarter.
- Over the last five years, EBIAT for TNXP hit a ceiling of -$15.8 million in Q3 2024 and a floor of -$77.3 million in Q2 2024.
- Median EBIAT over the past 3 years was -$27.7 million (2023), compared with a mean of -$31.3 million.
- Biggest five-year swings in EBIAT: plummeted 172.66% in 2024 and later skyrocketed 64.62% in 2025.
- Tonix Pharmaceuticals Holding's EBIAT stood at -$27.3 million in 2023, then increased by 16.7% to -$22.8 million in 2024, then tumbled by 106.26% to -$46.9 million in 2025.
- The last three reported values for EBIAT were -$46.9 million (Q4 2025), -$31.8 million (Q3 2025), and -$27.4 million (Q2 2025) per Business Quant data.